couter

MNKDMannKind Corporation

Health CarePharmaceuticals

The Read

2% in April-May 2026 driven by a short squeeze amid no major partnership announcement, then gained about 8.
Oct 15, 2026 — Major Competitor (GLP-1) Therapy Launch or Data Update
Chart by TradingView

The schedule

  • Thu15Oct

    Anticipated market expansion or readout from competing diabetes/obesity GLP-1 therapies.

  • Tue8Dec

    Expected regulatory milestone or pivotal data readout for the Technosphere inhaled therapeutics pipeline.

  • Wed20Jan

    Expected timeline for debt restructuring, strategic financing, or secondary offering to extend the cash runway.

  • Wed3Feb

    Q3 operational results, measuring market share retention against intensifying competitor volume.

  • Wed5May
  • Wed5May

Past

  • Wed5Aug

    Mid-year review of revenue generation, operating expenses, and confirmation of annual clinical timelines.

  • Wed6May

    Actual outcome: Bull · $3.25 at outcome

    MannKind reported a Q1 loss of $0.05 per share and missed revenue estimates amid ongoing margin pressures. However, the company simultaneously announced a new Ralinepag Dry Powder Inhalation (DPI) program in collaboration with United Therapeutics, securing a $5 million upfront payment and up to $35 million in potential milestones. Despite the weak headline financials, optimism surrounding this expanded partnership and pipeline advancement kept shares trading well above the $2.50 bull target.

    Q1 2026 earnings on 2026-05-06 will update Afrezza and Technosphere-based product trends and clarify how quickly MannKind is recovering from the weak Q4 2025 print. From a base of $2.10, solid top-line growth with better cost control could lift the stock toward $2.50, while another miss or a softer FY2026 outlook could drive shares down toward $2.50.

  • Wed15Apr

    Actual outcome: Bull · $3.09 at outcome

    Although MannKind did not announce the anticipated major Technosphere platform partnership in mid-April, a reported 29.8% spike in short interest likely set the stage for a short squeeze. This dynamic ultimately drove the stock well past the $3.40 bull target by early May, overcoming the absence of the specific fundamental catalyst.

    Potential announcement of a significant Technosphere platform partnership around 2026-04-15, which could validate MannKind's inhaled delivery technology and de-risk future royalty streams if economics and scope are attractive. At a base price of $2.57, a constructive deal could support a move toward $3.40, while a small or delayed partnership, or no announcement at all, could push the stock down toward $3.40.